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Abstract 
 
Background 
Amniotic fluid embolism (AFE) is a rare, but severe complication of pregnancy. A recent 
systematic review highlighted apparent differences in the incidence, with studies estimating 
the incidence of AFE to be more than three times higher in North America than Europe. The 
aim of this study was to examine population-based regional or national data from five high-
resource countries in order to investigate incidence, risk factors and outcomes of AFE and to 
investigate whether any variation identified could be ascribed to methodological differences 
between the studies. 
Methods 
We reviewed available data sources on the incidence of AFE in Australia, Canada, the 
Netherlands, the United Kingdom and the USA. Where information was available, the risk 
factors and outcomes of AFE were examined. 
Results 
The reported incidence of AFE ranged from 1.9 cases per 100 000 maternities (UK) to 6.1 
per 100 000 maternities (Australia).  There was a clear distinction between rates estimated 
using different methodologies. The lowest estimated incidence rates were obtained through 
validated case identification (range 1.9-2.5 cases per 100 000 maternities); rates obtained 
from retrospective analysis of population discharge databases were significantly higher 
(range 5.5-6.1 per 100 000 admissions with delivery diagnosis). There were no clear 
differences in mortality or case fatality rates. Older maternal age and induction of labour 
(varying methods) were consistently associated with AFE across all five countries. 
Conclusions/Key Recommendations 
Recommendation 1:  Comparisons of AFE incidence estimates should be restricted to 
studies using similar methodology. Depending on the available resources and research 
questions, the recommended approaches would be either population-based database 
studies using additional criteria to exclude false positive cases, or tailored data collection 
using existing population-based systems specifically designed to facilitate study of rare 
pregnancy conditions. 
Recommendation 2: Comparisons of AFE incidence between and within countries would be 
facilitated by development of an agreed case definition, particularly for non-fatal cases, and 
an agreed set of criteria to minimise inclusion of false positive cases for studies conducted 
using population-based databases. 
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Recommendation 3: Groups conducting detailed population-based studies on AFE should 
develop an agreed strategy to allow combined analysis of data obtained using consistent 
methodologies in order to identify potentially modifiable risk factors. 
Recommendation 4: Future specific studies on AFE should aim to collect information on 
management and longer-term outcomes for both mothers and infants in order to guide best 
practice, counselling and service planning. 
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Background 
Amniotic fluid embolism (AFE) is a rare, but severe complication of pregnancy. The rarity of 
the condition, and the fact that AFE is a diagnosis of exclusion, make it particularly 
challenging to study and therefore difficult to obtain reliable information about incidence, risk 
factors, management and outcomes. Centre-based studies, because of the small population 
they cover, or because of the long historical period which has to be studied in order to 
identify a sufficient number of cases, rarely generate robust and reproducible results which 
can be generalised to today’s obstetric populations. As AFE is infrequent, the most robust 
studies of the condition are population-based studies, ideally incorporating large numbers of 
pregnant women in order to have sufficient statistical power to generate stable incidence 
estimates and examine a range of risk factors to assess the independent risk associated 
with each. Multinational studies can enhance further the robustness, timeliness and hence 
utility of study results. 
 
A recent systematic review highlighted apparent differences in the incidence of AFE in 
different studies [1], with estimates being more than three times higher in North America 
than Europe [2-6]. The aim of this study was to examine population-based regional or 
national data within five high resource countries in order to investigate incidence, risk factors 
and outcomes of AFE and to investigate whether any variation identified could be ascribed to 
methodological differences between the studies.  
 
Methods 
We reviewed available data sources on the incidence of AFE in Australia, Canada, the 
Netherlands, the United Kingdom and the USA. Where information was available, data on 
the risk factors and outcomes of AFE were also reviewed. Because of variations in 
definitions of AFE used between countries and between data sources, we did not restrict our 
analysis to AFE defined using any one particular classification. The definitions and codes 
used to identify cases in each country are shown in table 1. 
Data sources 
Australia 
Fatal cases were identified through four published triennial Maternal Deaths in Australia 
reports [7-10].  The Maternal Deaths in Australia reports are a compilation of confidential 
death reviews conducted at the jurisdictional level. Information for incident cases (fatal and 
non-fatal) was obtained from the National Hospital Morbidity Database (NHMD) [11] an 
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administrative collection of hospital separations for the years 1994-2005. The NHMD is a 
collection of confidential summary records for admitted patients separated in public and 
private hospitals in Australia. The NHMD is based on data from the state and territory health 
authorities and is compiled nationally by the Australian Institute of Health and Welfare.  
Diagnoses and procedures were coded according to ICD10 AM (ICD-9 prior to 1999). 
Records were selected based on a diagnosis of AFE using ICD9CM code of 637.10-637.14 
with a birth code (V27.0-V27.2) or a code for care immediately following delivery (V24.0) or 
postpartum examination and care (V24.3). The ICD9 coding system includes a fifth digit (0-
4) for obstetric codes that indicates the timing of the diagnosis of the condition relative to the 
birth; and for ICD-10AM O88.1 with Z37.0-Z37.9 used to flag a birth episode and Z39.01 to 
flag an immediate postpartum episode.  Data were available for all jurisdictions in Australia, 
accounting for 100% of all women giving birth in hospital. 
 
In New South Wales (NSW) data on incident cases (fatal and non-fatal) were obtained from 
the Admitted Patient Data Collection (APDC), a census of all hospital discharges from public 
and private hospitals, and linked to the Midwives Data Collection (MDC), a legislated 
surveillance system of all births in NSW completed by attending midwives and doctors [12]. 
Diagnoses and procedures obtained from the medical records for each hospitalisation are 
coded according to the International Statistical Classification of Diseases and Related Health 
Problems, Australian Modification (ICD-10-AM) and the affiliated Australian Classification of 
Health Interventions. Data for 2001-2007 inclusive were examined. A previous validation 
study encountered only one case of AFE, and this was correctly coded [13]. 
 
Data for Victoria were derived from the Victorian Perinatal Data Collection (VPDC) which is 
completed by the birth attendant (usually the midwife) for each birth [14]. Diagnoses are 
coded according to ICD-10-AM (VPDC modification). Case validation was conducted 
through medical review of the Victorian Perinatal Data files of all cases identified. AFE 
diagnosis was confirmed if surviving mothers required admission to ICU, and/or had major 
blood transfusion of > 2 units, or pathology reports from autopsy were compatible with AFE.  
Canada 
As previously reported [4], information on incident cases (fatal and non-fatal) for Canada 
was based on all hospital deliveries as documented in the Discharge Abstract Database of 
the Canadian Institute for Health Information from 1991 to 2002, which records all deliveries 
in Canada with the exception of those in Quebec, Manitoba and Nova Scotia (thus 
approximately 70% of deliveries). All medical diagnoses were coded using the International 
Classification of Diseases (ICD-9 up to 2000, and a combination of ICD-9 and ICD-10 from 
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2001-2002), while procedures were coded using the Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures (CCP) for 1991-2001 and the Canadian Classification 
of Interventions (CCI) for 2001-2.  
 
The Netherlands 
Fatal cases were identified from the Dutch Confidential enquiries into the causes of maternal 
mortality between 1983 and 2005 [15]. Incident cases (fatal and non-fatal) were identified 
through the LEMMoN study of severe maternal morbidity between 2004 and 2006 [16]. In 
each hospital in the Netherlands with a consultant-led maternity unit, a nominated reporting 
clinician notified cases on a monthly basis using a standard web-based reporting form. For 
both fatal and incident cases, specific information on diagnosis, characteristics of the case 
and management was collected using a standardised form in addition to copies of selected 
anonymised parts of the case record. These data were used for subsequent case validation 
by the committee. 
 
United Kingdom 
Fatal cases were identified through the UK confidential enquiries into maternal deaths 
between 2003 and 2008 [17, 18]. 
 
UK data on incident cases of AFE (fatal and non-fatal) were obtained through the UK 
Obstetric Surveillance System (UKOSS) between February 2005 and January 2010 [3]. In 
each hospital in the UK with a consultant-led maternity unit, nominated reporting clinicians 
notified cases using a monthly reporting card. In response to a report of a case, clinicians 
were asked to complete a data collection form confirming the case definition, characteristics 
of the case, management and outcomes. 
 
United States 
Fatal cases were identified through the Pregnancy Mortality Surveillance System (PMSS) in 
the Division of Reprductive Health at the Centers for Disease Control and Prevention (CDC) 
[19]. Since 1986, PMSS has used matched vital records to identify deaths caused by 
pregnancy complications occurring during or within one year of the end of pregnancy.  
 
Non-fatal and fatal incident cases were obtained from the Nationwide Inpatient Sample (NIS) 
for 1999-2008.  The NIS is part of the Agency for Healthcare Research and Quality’s 
Healthcare Cost and Utilization Project. The NIS [20] contains data on 5 to 8 million hospital 
stays and, with appropriate weighting, generates a nationally representative sample of 
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inpatient hospital admissions.  The database contains up to 15 diagnosis fields and 15 
procedure fields; diagnoses and procedures are coded at the hospital at discharge using the 
ICD-9-CM. Except for age, the NIS does not collect individual demographic information nor 
does it report obstetrical characteristics for individual pregnancies except those that can be 
translated to ICD-9-CM codes.  Delivery hospitalisations were identified using a previously 
published algorithm based on ICD-9-CM diagnosis and procedure codes and diagnosis-
related group (DRG) codes [21].  
 
Statistical analyses 
Incidence rates with 95% confidence intervals were calculated using as a denominator the 
number of maternities, deliveries or live births recorded regionally or nationally during each 
study period. Putative risk factors, identified from factors previously reported in the literature, 
were examined using univariable or full multivariable logistic regression analysis where 
possible and results presented as odds ratios with 95% confidence intervals. Where 
individual level data were not available, associations were examined using risk ratios with 
95% confidence intervals.  
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Ethics Committee Approval 
The UK AFE study was approved by the London Multi-centre Research Ethics Committee 
(ref 04/MRE02/46) and the linkage and use of New South Wales data was approved by the 
NSW Population and Health Services Research Ethics Committee (2006-06-011). The Dutch 
LEMMoN study was centrally approved by the medical ethics committee of the Leiden 
University Medical Centre (ref P04-020). No other permissions were required for use of the 
data presented. 
 
Results 
Incidence 
The reported incidence of AFE ranged from 1.9 cases per 100 000 maternities (UK) to 6.1 
per 100 000 maternities (Australia) (Table 2). There was a clear distinction between rates 
estimated using different methodologies. The lowest estimated incidence rates were 
obtained through validated prospective case identification (range 1.9-2.5- cases per 100 000 
maternities); rates obtained from retrospective analysis of population discharge databases 
were significantly higher (range 5.5-6.1 per 100 000 admissions with delivery diagnosis), 
with an intermediate estimated incidence obtained from analysis of a regional discharge 
database in which additional criteria (at least one of the cardinal symptoms with no other 
potential explanation) were used to exclude false positive cases (3.3 cases per 100 000 
maternities). When the latter database was used without the additional selection criteria, the 
estimated incidence was 6.3/100,000. 
 
Mortality and case fatality 
Mortality ratios  ranged from 0.1 per 100 000 live births in the Netherlands from 1993-2005 
to 1.3 per 100 000 live births in the United States in 1997-2001 and Australia excluding 
Victoria. Case-fatality rates ranged from 11 to 43%. There were no clear differences in 
estimates of maternal mortality due to AFE or case fatality rates due to AFE using any 
different methodology, noting the limited power to detect differences due to small numbers of 
fatal cases (Tables 3 and 4). The studies with the highest case fatality rates (NSW and 
Victoria) were conducted using case validation. Note, however, the wide confidence intervals 
surrounding all case fatality estimates due to the rarity of the condition and the small 
numbers involved.  
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Associated factors 
The only factors consistently associated with AFE across all five countries were older 
maternal age; although the association was not statistically significant in the Dutch data, this 
could be due to limited study power since all cases occurred in women who were aged 29 
years or greater (Table 5), and induction of labour. However, the methods of induction 
investigated varied. UK and Dutch data show a significant association with induction of 
labour (all methods); in the Canadian population, an association was observed with medical 
induction of labour, whereas in New South Wales there was only a statistically significant 
association with medical induction using vaginal prostaglandin. In the US study, induction of 
labour (all methods) was associated with raised odds (aOR 1.5), but this was not statistically 
significant. Where data were available, there were increased odds of AFE associated with 
placenta praevia and placental abruption. For all of the other factors examined (Table 5), the 
associations varied in the direction of effect and statistical significance.  
 
Other associations were noted with mode of delivery: forceps/vacuum and caesarean 
section, although these are challenging to interpret since information on the timing of 
delivery in relation to the AFE was not available for all of the data sources. In the UK data, 
where timing of the event and delivery was available, there was a statistically significant 
association noted with caesarean section delivery when the AFE occurred after delivery. 
There was no association with forceps or vacuum delivery, although the small number of 
women with AFE who had operative vaginal deliveries means there is limited statistical 
power to examine this association. Of note, eclampsia, a condition which may form one of 
the differential diagnoses for AFE, was strongly associated with AFE in the Canadian and 
US studies which did not use additional criteria to exclude false positive cases. 
 
Very limited data were available on factors associated with fatality (Table 6); there were no 
factors consistently associated with fatality across all of the countries. 
Outcomes 
For the majority of sources used, there was very limited information on maternal outcomes 
other than death. Cerebral injury was noted in 6% of women with AFE in the UK, and 
cerebral infarction occurred in 20% of women with AFE in New South Wales. Data were 
similarly limited on fetal and infant outcomes. Eight of 21 infants (38%) born to mothers with 
AFE in the Netherlands were stillborn or died in the neonatal period; the figure was 5 of 75 
infants (7%) in the UK and 6 of 19 (32%) in NSW. 
 10 
 
Discussion 
Incidence of AFE 
This analysis demonstrates differences in the reported incidence of AFE in high-resource 
countries that vary according to the study methodology. Incidence estimates generated from 
analysis of population databases without additional criteria to exclude false positive cases 
produce more than double the estimates generated from analyses using specific validated 
case identification; an estimate from a population database analysis with additional criteria to 
exclude false positive cases was compatible with the estimates from the validated case 
identification studies. Comparison of the AFE incidence using a population database with 
and without criteria to exclude false positive cases also found this pattern, with the estimated 
incidence from the unselected population database double that when the additional criteria 
were used. This suggests that the noted European-North American differences in incidence 
[1] are also likely to be explained by the differences in methodology used, and may not 
represent a true difference in incidence between the countries.   
 
It is difficult to determine which of these estimates is likely to represent a value closest to the 
“true” incidence of AFE. The apparently lower case fatality amongst cases identified through 
database studies supports the argument that these studies include a number of false 
positive cases. The observed association with conditions which may form part of the 
differential diagnosis of amniotic fluid embolism, for example eclampsia, also supports this 
hypothesis. Conversely, the higher case fatality observed in studies with case validation may 
simply indicate that these studies identify more severe cases.  Database studies without 
case validation may thus have high sensitivity but conversely low positive predictive value 
due to the inclusion of a number of false positive cases, whereas studies with case validation 
may have lower sensitivity, due to lower case ascertainment and false negative cases, but 
higher positive predictive value. Perhaps the gold standard would be a database study with 
subsequent case validation through examination of the medical records. Such an approach, 
however, in the context of a rare condition such as AFE is difficult due to the large number of 
individual centres at which medical records would need to be accessed. All studies are 
complicated by the additional fact that AFE is a diagnosis of exclusion; internationally 
accepted diagnostic criteria for non-fatal cases do not exist, and there is a place for 
development of such criteria, using as a model, for example, the criteria used within the UK 
[3]. Differences in the case definitions used are likely to add to the observed variation in 
incidence estimates. 
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Thus the optimal approach to investigating AFE may be dependent on the purpose of the 
study, since each of the practical approaches has both advantages and disadvantages. 
Population-based database studies, where suitable sources of information exist, are likely to 
be the most economical option for studying the condition; however, there is likely to be a 
degree of inclusion of false positive cases, over-estimation of incidence and thus non-
uniformity of the cases examined. The use of additional criteria to exclude false positive 
cases within database studies, the approach taken in New South Wales [22], may overcome 
some of these issues. However, without review of the medical records, this approach may 
exclude true cases that have been poorly coded.  Database studies are also limited by a 
restricted number of available data items; according to the purpose of the original data 
collection, extremely limited information on management is available, and temporality of 
events, for example in relation to whether the AFE occurred before or after birth, cannot be 
studied. For the purposes of examining risk factors and management in detail, studies with 
specific prospective data collection methods may therefore be the best approach. Such 
studies are facilitated by available collaborations designed specifically to study rare 
pregnancy disorders, such as the approach taken by UKOSS [3], the Australasian Maternity 
Outcomes Surveillance System (AMOSS) and other members of the International Network of 
Obstetric Survey Systems (INOSS) [23].  
 
Recommendation 1:  Comparisons of AFE incidence estimates should be restricted to 
studies using similar methodology. Depending on the available resources and research 
questions, the recommended approaches would be either population-based database 
studies using additional criteria to exclude false positive cases, or tailored data collection 
using existing population-based systems specifically designed to facilitate study of rare 
pregnancy conditions.  
 
Recommendation 2: Comparisons of AFE incidence between and within countries would be 
facilitated by development of an agreed case definition, particularly for non-fatal cases, and 
an agreed set of criteria to minimise inclusion of false positive cases for studies conducted 
using population-based databases. 
 
Associated factors 
We identified very little consistency among countries in the factors associated with 
occurrence of AFE and no factors consistently associated with fatality from AFE. Maternal 
age appeared to be associated with the occurrence of AFE in all populations examined, and 
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this may therefore represent a true association, although the mechanisms by which older 
maternal age predisposes to AFE remain hypothetical and may include disruption of the 
uterine vasculature or minor degrees of abnormal placental invasion. The available 
information on placental abnormalities suggests that placenta praevia and placental 
abruption substantially increase (3-10 times) the risk of AFE. Given the differing 
methodologies and therefore differing biases due to potential inclusion of false positive 
cases or selection of more severe cases, other reported associations are very difficult to 
interpret. One of the most widely reported associations, with induction of labour, was noted 
to be statistically significant in some studies (UK, Netherlands), with only certain induction 
methods (Australia, Canada) or the association was not statistically significant, although the 
estimated odds ratio was compatible with those reported in most other studies (US). This 
illustrates the difficulties of comparing data across studies with differing case identification 
processes and definitions and varying levels of detail about individual risk factors.  
 
With other factors, such as mode of delivery, issues concerning the timing of the event make 
the data difficult to interpret. The data we examined were often limited either because the 
timing of the AFE in relation to the delivery was not available, and hence we were unable to 
identify cases in which a caesarean or operative vaginal delivery was a cause and not a 
consequence of the AFE. In the studies where timing was available, small numbers of 
women in certain subgroups, for example the number of cases undergoing operative vaginal 
delivery, limited statistical power. It is important to note, however, in the context of rising 
caesarean delivery rates worldwide, that there was a significant association with caesarean 
delivery in the one country (UK) in which we were able to investigate specifically cases 
where the AFE occurred after delivery. Analysis of pooled international data, obtained using 
consistent methodologies  with agreed definitions and case validation, would provide more 
reliable information on these associated factors and hence provide the potential to develop 
appropriate preventive strategies which would otherwise be limited. 
 
Recommendation 3: Groups conducting detailed population-based studies on AFE should 
develop an agreed strategy to allow combined analysis of data obtained using consistent 
methodologies in order to identify potentially modifiable risk factors. 
 
Outcomes 
There were no clear differences in maternal mortality ratios due to AFE between countries or 
by study methodology. Information on other outcomes for women was very limited, although 
data on cerebral injury [3] suggest that AFE may have a significant impact in the long term 
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outcomes of survivors, and this requires further investigation. None of the data sets included 
information on long-term maternal outcome after non-fatal AFE. Data on infant outcomes 
were only available for sources which can link data on the mother and infant or from studies 
which collect specific data. Although limited, the available data suggest the perinatal death 
rate associated with AFE is high (7-38%). Similarly, we were unable to investigate any 
potential relationship between management and outcomes because of extremely limited 
data. Further international collaborative studies using specific data collection would allow for 
more detailed investigation of the outcomes for mother and infant, over both short and longer 
term, and any relationship with management. 
 
 
Recommendation 4: Future specific studies on AFE should aim to collect information on 
management and longer-term outcomes for both mothers and infants in order to guide best 
practice, counselling and service planning. 
 
Strengths and limitations of this analysis 
This analysis used data from five high resource countries, and the results are thus 
generalizable only to countries with similar resource settings. As discussed above, data on 
AFE were obtained using different study methodologies, and therefore this limits the 
comparability of some of the results. AFE is a rare condition, and all studies have limited 
power to detect true associations as statistically significant. We hope that this may be 
addressed in the future by further international collaborative studies, an approach that we 
would advocate for research into all rare conditions in pregnancy. 
 
 
Conclusions 
This analysis has highlighted the benefits of detailed comparison of AFE incidence and 
ascertainment methods from different population-based studies and has identified a number 
of difficulties with making direct international comparisons. The study methodology impacts 
on estimates of disease incidence and case fatality, and may also account for 
inconsistencies in reported risk factors. There is a need for consistent study methodologies, 
including agreed case definition and case validation criteria. The use of such unified 
methodologies will allow for valid international comparisons of incidence in the future, and 
may permit pooling of international data to provide more reliable information on associated 
factors, management and outcomes, thus allowing for development of preventive and 
treatment strategies to improve outcomes of this rare but serious condition. 
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Table 1: Definitions and codes used for AFE 
 
Country 
ICD-9 
coding 
ICD-10 
Coding 
Other definition used 
Australia (NSW) N/A O88.1 
1) if not fatal, the hospital record had to include a 
diagnosis of one or more of cardiac arrest, 
hypotension syndrome, respiratory distress, 
coagulation defects, coma and/or seizure, and an 
absence of other medical conditions or potential 
explanations of the symptoms and signs[1] and 2) 
where death was the outcome, AFE had to be 
listed as the cause of death. 
Australia 
(Victoria) 
N/A O88.1  
Australia 
(national data) 
673.1 O88.1 
Review of maternal death by expert committee in 
conjunction with a cause of death of amniotic fluid 
embolism  
Canada 673.1 O88.1  
Netherlands N/A N/A 
- Reported as maternal mortality or severe 
maternal morbidity with AFE as diagnosis or in 
differential diagnosis 
- One or more of the following severe enough to 
require medical treatment: 
           Hypotension (and/or cardiac arrest) 
           Respiratory distress 
           Disseminated intravascular coagulation 
           Coma and/or seizures 
 - Absence of any other clear medical explanation 
for the clinical course. 
United Kingdom N/A N/A 
In the absence of any other clear cause 
 
EITHER 
Acute maternal collapse with one or more of the 
following features: 
Acute fetal compromise  
Cardiac arrest  
Cardiac rhythm problems  
Coagulopathy  
Hypotension  
Maternal hemorrhage  
Premonitory symptoms e.g. restlessness, 
numbness, agitation, tingling 
Seizure  
Shortness of breath 
Excluding: women with maternal hemorrhage as 
the first presenting feature, in whom there was no 
evidence of early coagulopathy or cardio-
respiratory compromise 
 
OR 
Women in whom the diagnosis was made at post-
mortem examination with the finding of fetal 
squames or hair in the lungs 
USA 673.1 N/A 
If not fatal, ICD-9CM code of 673.1.  
For fatal cases, coding indicating AFE as cause of 
death or major contributing factor to the death 
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Table 2: Incidence 
 
Validated case identification 
Country 
  
Years Cases AFE rate 95% CI 
UK 2005-
2010 
72 1.9/100 000 maternities 
(deliveries ≥ 24wks) 
1.5-2.4 
Netherlands  2004-
2006 
9 2.5/100 000 maternities 
(deliveries ≥ 24wks) 
1.3-4.8 
Victoria 2000-
2008 
14 2.4/100 000 maternities 
(deliveries >20wks,400g) 
1.3-4.0 
 
 
Population Database with additional criteria to exclude false positive case
Country 
s  
Years Cases AFE rate 95% CI 
Australia 
(NSW) 
2001-2007 20 3.3/100 000 maternities 
(deliveries >20w, 400g) 
1.9-4.7 
 
Population Database without additional criteri
Country 
a  
Years Cases AFE rate 95% CI 
US [NIS] 1999-2008 2226 5.5/100 000 admissions with 
delivery diagnosis 
5.5-5.5 
Canada 1991-2002 180 6.0/100 000 deliveries (>20w 
400g) 
5.3-7.1 
Australia 1994-2005 185 6.1/100 000 admission a with a 
delivery diagnosis (deliveries 
>20w, 400g) 
5.2-6.9 
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Table 3: AFE Mortality rates 
Validated case identification 
Country 
  
Years Cases Mortality 95% CI 
UK 2003-
2005 
17 0.8 per 100 000 
maternities 
0.5-1.3 
UK 2006-
2008 
13 0.6 per 100 000 
maternities 
0.3-1.0 
Netherlands 1983-
1992 
2 0.1 per 100 000 live 
births 
0.0-0.4 
Netherlands 1993-
2005 
11 0.4 per 100 000 live 
births 
0.2-0.8   
Australia (national) 1994-
2005 
33 1.1 per 100 000 
maternities 
0.7-1.4 
Australia (Victoria) 2000-
2008 
6 1.0 per 100 000 
maternities 
0.4-2.2 
 
Population Database with additional criteria to exclude false positive cases
Country 
   
Years Cases Mortality 95% CI 
Australia (NSW) 2001-2007 6 1.2 per 100 000 
maternities 
0.3-2.0 
 
Country 
Population Database without additional criteria 
Years Cases Mortality 95% CI 
US (PMSS) 1991-1996 237 0.9 per 100 000 live births 
* 
US (PMSS) 1997-2001 256 1.3 per 100 000 live 
birth 
* 
US (PMSS) 2002-2005 171 1.0 per 100 000 live 
births 
* 
Canada 1991-2002 24 0.8 per 100 000 
deliveries 
0.5-1.2 
*Based on data on all births therefore no confidence intervals quoted 
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Table 4: AFE case fatality 
Validated case identification 
Country 
  
Years Case fatality rate 95% CI 
UK 2005-2010 19% 11-30% 
Netherlands 2004-2006 11%  3-45% 
Australia (Victoria) 2000-2008 43%  18-71% 
 
Population Databases with additional criteria to exclude false positive case
Country 
s 
Years Case fatality rate 95% CI 
Australia (NSW) 2001-2007 35% 15-59% 
Population Databases without additional criteri
Country 
a  
Years Case fatality rate 95% CI 
US 
[PMSS+NIS] 
1993-1998 21% 18-22% 
US 
[PMSS+NIS] 
1999-2005 18% 17-21% 
Canada 
 
1991-2002 13% 8-19% 
Australia (national, NHMD) 1994-2005 14% 9-19% 
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Table 5 Factors associated with amniotic fluid embolism 
 
 Australia (NSW) 
 
Canada Netherlands UK US 
Maternal factors      
Age <20 years * aOR 0.2 (0.1-
0.96) 
No cases * aOR 0.4 (0.2-0.9) 
Age ≥ 35 years RR 4.8 (2.0, 12) aOR 1.9 (1.4-2.7) RR 2.4 (0.7-9.1) aORǂ 2.7 (1.4-5.1) aOR 2.2 (1.5-2.1) 
Multipara RR 3.7 (0.9, 8.1) * 
 
RR 6.6 (0.8-52.7) aORǂ 0.9 (0.5-1.7) * 
Smoked during pregnancy RR 1.5 (0.5, 4.6) * * aORǂ 0.9 (0.4-2.2) * 
Socioeconomic status Disadvantaged 
(lowest quartile) 
RR 1.6 (0.6, 4.0) 
* * 
Routine, manual 
occupation or 
unemployed 
aORǂ 0.5 (0.3-1.0) 
* 
Race/Ethnicity 
(Baseline group white or 
native born) 
East Asian 
country of birth 
RR 2.4 (0.8, 7.2) 
* Non-Western 
immigrants        
RR 1.3 (0.3-6.1) 
 
Black or other 
ethnic minority 
group aORǂ 1.2 
(0.5-2.6) 
African American 
aOR 2.4 (1.5-3.6) 
Other aOR 2.3 
(1.5-3.6) 
Diabetes (pregnancy and 
pre-pregnancy) 
* aOR 1.5 (0.6-3.8) 
 
* * aOR 2.3 (0.6-9.2) 
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Pregnancy factors      
Multiple pregnancy * OR 2.5 (0.9-6.2) RR 7.1 (0.9-56.5) 
 
aORǂ 5.3 (1.2-
23.0) 
* 
Previous caesarean RR 1.7 (0.5, 6.0) aOR 0.8 (0.5-1.2) * * aOR 0.9 (0.6-1.3) 
Hypertensive disorders 
 
Any hypertensive 
disorder 
RR 1.3 (0.3, 5.5) 
Pre-existing 
hypertension  
RR 9.5 (2.2, 41) 
Eclampsia aOR 
11.5 (2.8-48.6) 
Pre-eclampsia 
aOR 1.4 (0.8-2.5) 
* * Eclampsia aOR 
29.1 (7.1-119) 
Pre-eclampsia 
aOR 7.3 (4.3-
12.5) 
Placenta praevia RR 10.5 (1.4, 79)  
Praevia or 
abruption aOR 3.5 
(2.3-5.5) 
* aORǂ 15.6 (2.5-
98.8) 
 
aOR 30.4 (15.4-
60) 
Placental abruption RR 13.3 (1.8, 100)  * aORǂ 17.3 (1-
304.1) 
aOR 8.0 (4.0-
15.9) 
Non-vertex at delivery RR 6.8 (2.4, 18.8) * RR 2.4 (0.3-19.4) * * 
Chorioamnionitis No cases aOR 1.4 (0.6-3.2) * * aOR 1.6 (0.7-3.4 
Polyhydramnios * aOR 3.0 (1.2-7.3) * * * 
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Induction of labour       
Induction of labour (all 
methods) 
* * RR 5.6 (1.5-20.9) 
 
aORǂ 3.5 (1.9-6.7) aOR 1.5 (0.9-2.3) 
Specific methods of 
induction 
     
 Any medical 
 induction of labour 
RR 1.9 (0.8, 4.9) aOR 1.8 (1.3-2.7) *   
 Surgical induction of 
 labour/artificial 
 rupture of 
 membranes 
RR 1.4 (0.6, 3.5) 1.0 (0.6-1.8) * * * 
 Vaginal 
 prostaglandin (PG) 
 E2 (induction) 
RR 3.4 (1.3, 9.0) * * * * 
 Any oxytocin  RR 0.8 (0.3, 2.3) * * * * 
 Induction with both 
 PG+oxytocin 
RR 2.1 (0.5., 9.1) * * * * 
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Delivery      
Mode of delivery      
(baseline group normal 
vaginal delivery) 
caesarean section 
After labour RR 
48.5 (6.1, 380) 
Without labour RR 
8.1 (0.7, 89) 
caesarean section 
Cephalic aOR 
12.5 (7.9-19.9) 
Non-cephalic aOR 
8.6 (4.3-17.4) 
 
caesarean section 
RR 2.2 (0.5-11.1) 
 
 
Cases occurring 
post delivery 
only  
caesarean section 
aOR   20.3 (4.3-
95.3) 
caesarean section 
aOR 5.7 (3.7-8.7) 
 
   instrumental  
RR 36.0 (4.4, 300) 
Forceps aOR 5.9 
(3.4-10.3) 
Vacuum aOR 2.9 
(1.6-5.3) 
Vacuum RR 1.5 
(0.2-12.3) 
 
Forceps or 
vacuum aOR  
11.6 (1.7-79.8) 
 
Forceps aOR 4.3 
(1.9-7.6) 
Vacuum aOR 1.9 
(1.0-3.7) 
   vaginal breech 
birth  
RR 151 (9.4, 
2400) 
  All cases 
Caesarean 
section aOR¥ 23.3 
(7.8-69.7) 
Forceps or 
vacumm aOR¥ 8.9 
(2.0-39.5) 
 
Manual removal of placenta 
(vaginal births) 
RR 19.4 (3.9, 96) * * * * 
Macrosomia * aOR 1.6 (0.9-3.0) * OR 2.4 (0.7-8.1) * 
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Gestational age 
 
 
<37 weeks 
RR 1.9 (0.4, 8.6) 
37-40 weeks  
1.0 (referent) 
≥ 41 weeks  
RR 1.7 (0.6, 4.8) 
>42 weeks 
aOR 1.4 (0.9-2.3) 
 
<37 weeks 
RR 9.7 (2.3-40.8) 
>42 weeks 
RR 3.2 (0.4-25.8) 
 
≥41 weeks 
aORǂ 0.4 (0.2-1) 
* 
ǂ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, multiple pregnancy, placenta praevia, placenta 
abruption, labour induction and postdates  
* No data or no accurate or limited data 
 Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, placenta praevia, placenta abruption, labour induction, 
postdates and mode of delivery 
¥ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, multiple pregnancy, placenta praevia, placenta 
abruption, labour induction, postdates and mode of delivery 
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 Table 6   Factors associated with fatality amongst AFE cases (risk ratio (RR) unless indicated) 
Condition or procedure Australia (NSW) Canada UK US 
Age ≥ 35 years 1.1 (0.5, 2.4) * aORǂ 2.8 (0.5-14.2) * 
Multipara 1.1 (0.7, 1.7) * aORǂ 0.9 (0.2-4.2) * 
Smoked during pregnancy 1.4 (0.3, 6.5 * *  
Socioeconomic status Disadvantaged 
(lowest quartile) 
1.4 (0.4, 4.5) 
* 
Routine, manual occupation or 
unemployed 
aORǂ 1.2 (0.3-5.6) 
 
Income $35,000+ aOR 
0.3 (0.1-1.0) 
Race/ethnicity   Black or other ethnic minority 
group vs white aORǂ 6.3 (1.1-
34.9) 
 
     
Previous CS 1.1 (0.1, 9.7 * * aOR 1.1 (0.3-3.9) 
Induction  OR 3.5 (1.5-8.4) aORǂ 1.9 (0.4-9.2) aOR 0.7 (0.1-3.3) 
 Medical induction of 
 labour 
1.6 (0.5, 5.1) * *  
 PG+Oxytocin 2.2 (0.2, 29) * * * 
General anaesthesia 1.6 (0.8, 2.9)    
Epidural anaesthesia 2.2 (0.2, 29)    
Mode of delivery 
   
   
Forceps/vacuum 
0.4 (0.1, 2.9) 
 
 
CS 1.8 (0.9, 3.6) 
*  Forceps 
aOR 1.7 (0.2-14.7) 
Vacuum 
aOR 0.7 (0.1-5.0) 
CS aOR 0.8 (0.2-2.8) 
* No data or no accurate or limited data 
ǂ Adjusted for age, parity, socioeconomic status, ethnicity and labour induction  
 
